Dietary Intervention With Únicla Dairy Products (DANTIAN) (DANTIAN)

August 20, 2021 updated by: María Reyes Pérez Fernández, Cooperativas Lacteas Unidas

Dietary Intervention With Únicla Dairy Products, Naturally Enriched With Selenium and Omega-3 Fatty Acids, May Improve Thyroid-stimulating Hormone (TSH) Levels in Women With Subclinical Hypothyroidism

Dietary intervention with Únicla dairy products, naturally enriched with selenium and omega-3 fatty acids, may improve thyroid-stimulating hormone (TSH) levels in women with subclinical hypothyroidism

Study Overview

Detailed Description

To analyze in women diagnosed with subclinical hypothyroidism, the effects of consumption of dairy products rich in selenium and omega-3 on symptoms related to thyroid disease and blood lipid profile, inflammatory response, and fatty acid levels in the red blood cell membrane among others.

Study Type

Interventional

Enrollment (Anticipated)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Diagnosis of subclinical hypothyroidism
  • TSH levels between 3 and 10 mIU / L
  • Normal levels of free triiodothyronine ( T3) and free thyroxine (T4)
  • Without previous or current treatment with levothyroxine

Exclusion Criteria:

  • Thyroid surgery or reception of radioactive iodine in a previous period of 12 months
  • History of cardiovascular disease and / or thrombosis
  • Established diagnosis or clinical suspicion of kidney or liver failure, chronic infections, blood diseases, type I diabetes and type II diabetes
  • Drug treatments that affect thyroid function (corticosteroids, amiodarone, propranolol, lithium)
  • Statin treatment and / or hormone replacement therapy
  • Adjuvant treatment with trace elements, vitamins or antidepressant and antipsychotic drugs
  • Hospitalization for serious illness or elective surgery in the past 4 weeks
  • Diseases and / or treatments that affect intestinal absorption (proton pump inhibitors)
  • Pregnant, planning to become pregnant or breastfeeding women
  • Consumption of ω-3 PUFA type food supplements
  • Intolerance and / or allergy to lactose and / or cow's milk proteins
  • Any pathology that requires close control, advises against their participation or there is an inability to move independently
  • Habitual residence outside the study's influence area
  • Participation in another clinical trial with drugs, or in other experimental studies
  • Refuse to sign the informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention/treatment

Dairy foods made with UNICLA milk Participants (n = 45) ingested UNICLA milk and dairy products (yogurt and cheese) for three months.

UNICLA milk is characterised by an improved nutritional composition, obtained by modifying cow's diet, feeeding the dairy cows with a sufficient and balanced ration, which recreates the fatty acid profile of the spring.

This ration includes pastures, high-quality forages and, among other components, a significant amount of flax seeds, which constitute a source of unsaturated fatty acids such as omega-3 and selenised yeast, as a source of organic selenium.

Consequently, UNICLA milk and dairy products are naturally enriched in selenium and ω-3 PUFA.

The daily intake reflects the usual consumption habits, being the recommended amounts of 200 ml of milk and 125 g of yogurt per day and 400g of fresh cheese per week

UNICLA milk naturally enriched in selenium and omega-3.
Other Names:
  • ÚNICLA milk
UNICLA yogur naturally enriched in selenium and omega-3.
Other Names:
  • ÚNICLA yogur
UNICLA fresh cheese naturally enriched in selenium and omega-3.
Other Names:
  • ÚNICLA fresh cheese
Placebo Comparator: Conventional milk

Participants (n = 45) ingest milk and conventional dairy products daily for 3 months.

Daily intake reflects usual dairy consumption habits in "real life" conditions, without forcing or inducing increased consumption. Therefore, the recommended amounts are 200 ml of milk and 125 g of yogurt per day and 400 g of fresh cheese per week

Conventional milk
Other Names:
  • Conventional milk
Conventional yogur
Other Names:
  • Conventional yogur
Conventional fresh cheese
Other Names:
  • Conventional fresh cheese

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of patients with changes in thyroid function
Time Frame: 3 months
thyroid stimulating hormone blood level
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
HDL level
Time Frame: 3 months
high density lipoproteins blood level
3 months
selenium
Time Frame: 3 months
selenium blood level
3 months
IL-6
Time Frame: 3 months
Interleukina-6 blood level
3 months
Fecal calprotectin
Time Frame: 3 months
Fecal calprotectin feces level
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Maria Reyes Pérez- Fernández, PhD, Galicia sur sanitary research institute

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

September 6, 2021

Primary Completion (Anticipated)

December 30, 2021

Study Completion (Anticipated)

May 30, 2022

Study Registration Dates

First Submitted

August 13, 2021

First Submitted That Met QC Criteria

August 20, 2021

First Posted (Actual)

August 24, 2021

Study Record Updates

Last Update Posted (Actual)

August 24, 2021

Last Update Submitted That Met QC Criteria

August 20, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • CLUN-20191005

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Subclinical Hypothyroidism

Clinical Trials on Experimental milk

Subscribe